Recent progress in development of dopamine receptor subtype-selective agents: Potential therapeutics for neurological and psychiatric disorders

被引:330
|
作者
Zhang, Ao [1 ]
Neumeyer, John L.
Baldessarini, Ross J.
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Bioorgan & Med Chem Lab, Shanghai 201203, Peoples R China
[2] Harvard Univ, Sch Med, McLean Hosp, Med Chem Lab, Belmont, MA 02478 USA
[3] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA
[4] Harvard Univ, Sch Med, Program Neurosci, Belmont, MA 02178 USA
[5] McLean Hosp, Neuropharmacol Lab, Belmont, MA 02478 USA
关键词
D O I
10.1021/cr050263h
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This review covers progress during 2000-2005 on the development of selective ligands targeting mainly to the five main dopamine (DA) receptors. Topics discussed include the pharmacology of dopamine receptor subtypes and the development of dopamine receptor subtype ligands. As for the latter, emphasis is on the receptor-selective ligands from D1 to D4. Generally, recent efforts in medicinal chemistry and neuropharmacology have yielded substantial numbers of compounds with activity and selectivity at each of these major DA receptors.
引用
收藏
页码:274 / 302
页数:29
相关论文
共 50 条
  • [1] Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders
    Ye, Na
    Neumeyer, John L.
    Baldessarini, Ross J.
    Zhen, Xuechu
    Zhang, Ao
    CHEMICAL REVIEWS, 2013, 113 : PR123 - PR177
  • [2] Development of subtype-selective oestrogen receptor-based therapeutics
    Stefan Nilsson
    Konrad F. Koehler
    Jan-Åke Gustafsson
    Nature Reviews Drug Discovery, 2011, 10 : 778 - 792
  • [3] Development of subtype-selective oestrogen receptor-based therapeutics
    Nilsson, Stefan
    Koehler, Konrad F.
    Gustafsson, Jan-Ake
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (10) : 778 - 792
  • [4] Development of subtype-selective nicotinic receptor ligands as receptor antagonists at the dopamine-releasing receptor subtype.
    Crooks, PA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U911 - U911
  • [5] Subtype-Selective Dopamine Receptor Radioligands for PET Imaging: Current Status and Recent Developments
    Banerjee, A.
    Prante, O.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (23) : 3957 - 3966
  • [6] The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents
    Lloyd, GK
    Menzaghi, F
    Bontempi, B
    Suto, C
    Siegel, R
    Akong, M
    Stauderman, K
    Velicelebi, G
    Johnson, E
    Harpold, MM
    Rao, TS
    Sacaan, AI
    Chavez-Noriega, LE
    Washburn, MS
    Vernier, JM
    Cosford, NDP
    McDonald, LA
    LIFE SCIENCES, 1998, 62 (17-18) : 1601 - 1606
  • [7] Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents
    Dwoskin, LP
    Sumithran, SP
    Zhu, J
    Deaciuc, AG
    Ayers, JT
    Crooks, PA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (08) : 1863 - 1867
  • [8] Subtype-selective GABAA receptor mimetics—novel antihyperalgesic agents?
    Hanns Ulrich Zeilhofer
    Robert Witschi
    Katharina Hösl
    Journal of Molecular Medicine, 2009, 87 : 465 - 469
  • [9] Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders
    Luedtke, RR
    Mach, RH
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (08) : 643 - 671
  • [10] Recent Progress in the Development of Subtype Selective Nicotinic Acetylcholine Receptor Ligands
    Astles, P. C.
    Baker, S. R.
    Boot, J. R.
    Broad, L. M.
    Dell, C. P.
    Keenan, M.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (04) : 337 - 348